ESMO Annual Meeting
October 17 – 21, 2025 | Berlin, Germany

As part of scientific exchange, Novartis is providing the most recent abstract(s) and/or presentation(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access. This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
For distribution in response to an unsolicited request for medical information subject to local approval.

Content to be used in accordance with local CPO guidelines

List of Presentations

Trial in Progress: A Phase Ib/II Study Assessing [177Lu]Lu-DOTA-TATE Plus Standard of Care as a First-line Treatment for Patients With Extensive-Stage Small Cell Lung Cancer

Luis Paz-Ares, David Planchard, Ken Herrmann, Zhonglin Hao, Tony S.K. Mok, Yongmin Liu, Riccardo Belli, Stephen V. Liu

  • e-Poster Presentation #2798eTiP
    Saturday, October 18, 2025 (e-poster)

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound